Price Alert

Prothena Corporation (PRTA)

NASDAQ: PRTA · Real-Time Price · USD

10.36

0.60 (6.15%)

At close: Oct 01, 2025, 1:53 PM

6.15% (1D)

Bid	10.35
Market Cap	557.68M
Revenue (ttm)	10.34M
Net Income (ttm)	-302.92M
EPS (ttm)	-5.83
PE Ratio (ttm)	-1.78
Forward PE	65.07
Analyst	Hold
Dividends	n/a

Ask	10.37
Volume	557,005
Avg. Volume (20D)	927,650
Open	9.79
Previous Close	9.76
Day's Range	9.79 - 10.46
52-Week Range	4.32 - 18.88
Beta	-0.04
Ex-Dividend Date	n/a

About PRTA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PRTA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PRTA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Prothena Corporation is scheduled to release its earnings on Nov 11, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+2.51%

PRTA stock has given up its prior loss. Prothena s... Unlock content with Pro Subscription

1 month ago

+2.51%

Prothena shares are trading lower after the company reported Phase 1 results for PRX012.

News

2 weeks ago · zacks.com

Prothena Down 40% Year to Date: What Lies Ahead for the Stock?

Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.

3 weeks ago · zacks.com

Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue?

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?

1 month ago · businesswire.com

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced that Novo Nordisk communicated that they expect to advance coramitug into a Phase 3 program for ATTR-CM in 2025.

1 month ago · fool.com

Prothena Q2 Revenue Drops 97%

Prothena (PRTA 3.96%), a biotechnology company focused on developing therapies for neurodegenerative diseases, released its second quarter 2025 results on August 4, 2025. The period saw notably weaker...

1 month ago · zacks.com

Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates

Prothena (PRTA) came out with a quarterly loss of $1.86 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to earnings of $1.22 per share a year ago.

2 months ago · businesswire.com

Prothena to Report Second Quarter 2025 Financial Results on August 4

DUBLIN--(BUSINESS WIRE)--Prothena today announced that it will report its second quarter and first six months of 2025 financial results on August 4, 2025.

2 months ago · zacks.com

PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?

Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD.